Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted EBITDA Margin of 191.57% for Q1 2026, down 1339.47% on a QoQ basis from 15.46% in Q4 2025, and down 26181.0% year-over-year from N/an in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 191.57% for Q1 2026.
- Quarterly EBITDA Margin fell 26181.0% year-over-year to 191.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.67% (down 1393.0% YoY) and the FY2025 annual result came in at 11.86%, up 1693892.0% from the prior year.
- EBITDA Margin was 191.57% for Q1 2026 at Arrowhead Pharmaceuticals, down from 15.46% in the prior quarter.
- Across five years, EBITDA Margin topped out at 70.24% in Q1 2025 and bottomed at 6456.48% in Q4 2024.
- A 5-year average of 914.72% and a median of 208.26% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin slumped 377789 bps — and 2025, when it soared 647194 bps.
- Arrowhead Pharmaceuticals' EBITDA Margin stood at 67.36% in 2022, then sank by 5608 bps to 3845.25% in 2023, then plunged by 68 bps to 6456.48% in 2024, then soared by 100 bps to 15.46% in 2025, then slumped by 1339 bps to 191.57% in 2026.
- Business Quant data shows ARWR's EBITDA Margin at 191.57% in Q1 2026, 15.46% in Q4 2025, and 17.2% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | -191.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -191.57% |
| Dec 31, 2025 | 15.46% |
| Sep 30, 2025 | 17.20% |
| Jun 30, 2025 | -596.21% |
| Mar 31, 2025 | 70.24% |
| Dec 31, 2024 | -6,456.48% |
| Dec 31, 2023 | -3,845.25% |
| Sep 30, 2023 | -672.98% |
| Jun 30, 2023 | -648.99% |
| Mar 31, 2023 | 32.93% |
| Dec 31, 2022 | -67.36% |
| Sep 30, 2022 | -265.49% |
| Jun 30, 2022 | -224.94% |
| Mar 31, 2022 | 27.37% |
| Dec 31, 2021 | -230.77% |
| Sep 30, 2021 | -169.48% |
| Jun 30, 2021 | -69.44% |
| Mar 31, 2021 | -86.04% |
| Dec 31, 2020 | -112.91% |
| Sep 30, 2020 | -656.62% |